High‐resolution metabolomic profiling of Alzheimer’s disease in plasma
Open Access
- 11 December 2019
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 7 (1) , 36-45
Abstract
Background: Alzheimer’s disease (AD) is a complex neurological disorder with contributions from genetic and environmental factors. High‐resolution metabolomics (HRM) has the potential to identify novel endogenous and environmental factors involved in AD. Previous metabolomics studies have identified circulating metabolites linked to AD, but lack of replication and inconsistent diagnostic algorithms have hindered the generalizability of these findings. Here we applied HRM to identify plasma metabolic and environmental factors associated with AD in two study samples, with cerebrospinal fluid (CSF) biomarkers of AD incorporated to achieve high diagnostic accuracy.Methods: Liquid chromatography‐mass spectrometry (LC–MS)‐based HRM was used to identify plasma and CSF metabolites associated with AD diagnosis and CSF AD biomarkers in two studies of prevalent AD (Study 1: 43 AD cases, 45 mild cognitive impairment [MCI] cases, 41 controls; Study 2: 50 AD cases, 18 controls). AD‐associated metabolites were identified using a metabolome‐wide association study (MWAS) framework.Results: An MWAS meta‐analysis identified three non‐medication AD‐associated metabolites in plasma, including elevated levels of glutamine and an unknown halogenated compound and lower levels of piperine, a dietary alkaloid. The non‐medication metabolites were correlated with CSF AD biomarkers, and glutamine and the unknown halogenated compound were also detected in CSF. Furthermore, in Study 1, the unknown compound and piperine were altered in MCI patients in the same direction as AD dementia.Conclusions: In plasma, AD was reproducibly associated with elevated levels of glutamine and a halogen‐containing compound and reduced levels of piperine. These findings provide further evidence that exposures and behavior may modify AD risks.Keywords
Funding Information
- National Institute of Environmental Health Sciences (P30 ES019776, T32 ES012870)
- National Institute on Aging (K23 AG042856, P50 AG025688, R21 AG043885)
This publication has 71 references indexed in Scilit:
- Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer’s Disease Using MetabolomicsPLOS ONE, 2013
- Alterations in metabolic pathways and networks in Alzheimer’s diseaseTranslational Psychiatry, 2013
- Hybrid Feature Detection and Information Accumulation Using High-Resolution LC–MS Metabolomics DataJournal of Proteome Research, 2013
- An accelerated workflow for untargeted metabolomics using the METLIN databaseNature Biotechnology, 2012
- High-performance metabolic profiling of plasma from seven mammalian species for simultaneous environmental chemical surveillance and bioeffect monitoringToxicology, 2012
- The sva package for removing batch effects and other unwanted variation in high-throughput experimentsBioinformatics, 2012
- Metabolome in progression to Alzheimer's diseaseTranslational Psychiatry, 2011
- Roles of glutamine in neurotransmissionNeuron Glia Biology, 2010
- Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairmentActa Neuropathologica, 2010
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009